

# Competitive endogenous RNA (ceRNA) regulation network of lncRNAs, miRNAs, and mRNAs in Wilms tumour

**fucai tang**

The Eighth Affiliated Hospital, Sun Yat-sen University

**zechao Lu**

First Clinical College of Guangzhou Medical University

**jiamin wang**

Guangdong Provincial Work Injury Rehabilitation Center

**zhibiao Li**

Third Clinical College of Guangzhou Medical University

**weijia Wu**

The Eighth Affiliated Hospital, Sun Yat-sen University

**Haifeng Duan**

Department of Urology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University

**zhaohui He** (✉ [gzyhzh@163.com](mailto:gzyhzh@163.com))

The Eighth Affiliated Hospital, Sun Yat-sen University <https://orcid.org/0000-0003-2289-9603>

---

## Research article

**Keywords:** Wilms tumour, Long noncoding RNA, Prognosis, Competing endogenous RNA network, MicroRNAs

**Posted Date:** December 9th, 2019

**DOI:** <https://doi.org/10.21203/rs.2.11185/v5>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on December 16th, 2019. See the published version at <https://doi.org/10.1186/s12920-019-0644-y>.

# Abstract

**Background:** Competitive endogenous RNAs (ceRNAs) have revealed a new mechanism of interaction between RNAs. However, an understanding of the ceRNA regulatory network in Wilms tumour (WT) remains limited. **Methods:** The expression profiles of mRNAs, miRNAs and lncRNAs in Wilms tumour samples and normal samples were obtained from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database. The EdgeR package was employed to identify differentially expressed lncRNAs, miRNAs and mRNAs. Functional enrichment analyses via the ClusterProfile R package were performed, and the lncRNA–miRNA–mRNA interaction ceRNA network was established in Cytoscape. Subsequently, the correlation between the ceRNA network and overall survival was analysed. **Results:** A total of 2,037 lncRNAs, 154 miRNAs and 3,609 mRNAs were identified as differentially expressed RNAs in Wilms tumour. Of those, 205 lncRNAs, 26 miRNAs and 143 mRNAs were included in the ceRNA regulatory network. The results of Gene Ontology (GO) analysis revealed that the differentially expressed genes (DEGs) were mainly enriched in terms related to response to mechanical stimuli, transcription factor complexes, and transcription factor activity (related to RNA polymerase II proximal promoter sequence-specific DNA binding). The results of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that the DEGs were mainly enriched in pathways related to the cell cycle. The survival analysis results showed that 16 out of the 205 lncRNAs, 1 out of 26 miRNAs and 5 out of 143 mRNAs were associated with overall survival in Wilms tumour patients ( $P < 0.05$ ). **Conclusions:** CeRNA networks play an important role in Wilms tumour. This finding might provide effective, novel insights for further understanding the mechanisms underlying Wilms tumour.

## Background

Wilms tumour (WT) is the most common type of paediatric renal malignancy. WT patients have a poor prognosis, although the 5-year overall survival rate is constantly improving with the advancement of disease-associated therapies [1]. Chemotherapy, surgery and radiation therapy are the main treatment strategies for WT. However, 50% of children who have a recurrence after these treatments die from this tumour [2, 3]. Novel therapeutic treatments targeting specific mechanisms of WT are still lacking.

Previous studies have demonstrated that numerous key long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and mRNAs are closely related to the pathogenesis of WT, such as LINC00473 [4], miR-483-5p [5], miR-195 [4] and HACE1 [6]. However, there are few reports on the development of prognostic biomarkers in WT. If WT patients who were more likely to have a poor prognosis according to these prognosis biomarker results could be identified, clinicians might be able to apply more aggressive and individualized treatment. Therefore, prognostic biomarkers and targeted therapies in WT need to be identified to improve the clinical outcomes.

In the last decade, the complexity of the human genome has been revealed by advanced RNA sequencing analysis [7]. Under such circumstances, competing endogenous RNA (ceRNA) analyses have demonstrated that lncRNAs can communicate with common miRNA response elements and miRNAs to

construct an intricate interconnected network and ultimately crosstalk with mRNA. The involvement of the ceRNA regulatory network in tumour initiation and progression has been validated in previous studies [8, 9]. However, the specific ceRNA regulatory network (lncRNA–miRNA–mRNA) in WT remains to be elucidated.

In the present study, a ceRNA regulatory network (205 mRNAs, 26 lncRNAs and 143 miRNAs) was constructed to promote the understanding of how lncRNAs sponge miRNA to regulate gene expression in WT. Subsequently, survival analysis and functional analysis were used to promote a new understanding of the role of the ceRNA regulatory network in WT carcinogenesis. The present study might provide insight into the molecular mechanisms that participate in the progression and tumorigenesis of WT.

## Methods

### *Data collection and preprocessing*

Data were retrieved from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET: <https://ocg.cancer.gov/programs/target>; date: 12 February 2019) database. The data (of lncRNAs, mRNAs and miRNAs) in the present study are publicly available. Ethics committee approval was not required because the data in the present study were obtained from the TARGET database. Among the data, miRNA expression data were acquired from 138 samples, including 6 normal samples and 132 WT samples. In addition, mRNA and lncRNA expression data were acquired from 132 samples, including 6 normal samples and 126 WT samples. The differentially expressed lncRNAs (DELs), differentially expressed miRNAs (DEMs) and differentially expressed genes (DEGs) between WT and normal samples were determined via the EdgeR package in the R software (version 3.3.2). For the cut-off criteria, a  $|\log_{2}(\text{fold change})| > 1$  and a false discovery rate (FDR) of  $< 0.05$  were used. A flow chart of the analysis procedure is shown in Figure 1.

### *Prediction of lncRNA–miRNA and miRNA–mRNA interactions*

DEL-DEM-DEG interactions were divided into DEL-DEM and DEM-DEG pairs. The StarBase database (<http://starbase.sysu.edu.cn/>) was employed to change the miRNA sequences. MiRcode [10] (<http://www.mircode.org/>) is an effective online software that provides the interactions between lncRNAs and miRNAs. MiRTarBase [11] (<http://mirtarbase.mbc.nctu.edu.tw>), miRDB [12] (<http://www.mirdb.org/miRDB/>), and TargetScan [13] (<http://www.targetscan.org/>) are online tools that were used to retrieve and predict target mRNAs of the miRNAs. A Venn diagram was constructed to obtain the overlapping portion of target miRNAs and mRNAs. Matched DEL-DEM and DEM-DEG interactions were screened for further bioinformatics analysis.

### *CeRNA network construction and functional enrichment analysis*

Cytoscape software (Version 3.6.1) was utilized to construct and visualize the DEL-DEM-DEG ceRNA network. Cytoscape was used to visualize the molecular interaction networks according to gene expression profiles and annotations. To better comprehend the tumorigenesis mechanisms in WT, Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of DEGs in the ceRNA network were performed via the ClusterProfile R package. An FDR <0.05 was used as a cut-off value.

### ***Survival analysis***

Identification of prognostic DEL, DEM and DEG signatures were executed via the log-rank test and Kaplan-Meier analysis. The survival curves were constructed using the 'survival' package. Survival analysis was performed according to Kaplan-Meier univariate survival analysis. P<0.05 was selected as the statistical threshold value. All survival analyses were conducted using R software (version: 3.3.2).

## **Results**

### ***DEL, DEG and DEM identification in WT***

LncRNA, mRNA, and miRNA expression profiles between WT samples and normal samples acquired from TARGET were analysed in the present study. A total of 2,037 DELs, 154 DEMs and 3,609 DEGs were identified in the present study. A total of 1,247 upregulated and 790 downregulated DELs were identified in WT with a cut-off threshold of a  $|\log_{2}(\text{fold change})| > 1$  and a false discovery rate (FDR) of <0.05. The distribution of DELs between WT and normal controls is presented as a heatmap plot in Figure 2a. According to the cut-off threshold of a  $|\log_{2}(\text{fold change})| > 1$  and a false discovery rate (FDR) of <0.05, 105 upregulated and 49 downregulated DEMs were identified in WT. A heatmap plot of the related DEMs between WT and normal controls is shown in Figure 2b. A total of 1,894 upregulated and 1,715 downregulated DEGs were identified in WT. The DEG distribution between WT and normal controls is presented as a heatmap plot in Figure 2c. The top 10 upregulated and downregulated DELs, DEMs and DEGs are shown in Table 1.

### ***CeRNA network construction and functional enrichment analysis***

A dysregulated lncRNA-miRNA-mRNA ceRNA network in WT was constructed according to the interactions of 980 DEL-DEM pairs and 235 DEM-DEG pairs between 205 DELs, 26 DEMs, and 143 DEGs. The ultimate lncRNA-miRNA-mRNA ceRNA regulatory network visualized in Cytoscape is presented in Figure 3.

GO and KEGG analyses were also performed to reveal the functions of the 143 DEGs that were included in the ceRNA network (see Table 2). The DEGs were enriched in 99 "biological processes (BP)" terms, and

the top five terms were response to mechanical stimulus, G1/S transition of mitotic cell cycle, cell cycle G1/S phase transition, muscle cell proliferation, and mesenchymal cell differentiation. The DEGs were enriched in 8 “cellular component (CC)” terms, and the top five terms were transcription factor complex, cyclin-dependent protein kinase holoenzyme complex, nuclear chromatin, nuclear transcription factor complex, and Flemming body. The DEGs were enriched in 10 “molecular function (MF)” terms. The top five terms were transcription factor activity (related to RNA polymerase II proximal promoter sequence-specific DNA binding), transcriptional activator activity (related to RNA polymerase II transcription regulatory region sequence-specific DNA binding), proximal promoter sequence-specific DNA binding, transcriptional activator activity (related to RNA polymerase II proximal promoter sequence-specific DNA binding), and transcriptional repressor activity (related to RNA polymerase II transcription regulatory region sequence-specific DNA binding). Additionally, KEGG pathway analysis showed that DEGs were enriched in 30 pathways, such as pathways related to cell cycle, small-cell lung cancer, p53 signalling, microRNAs in cancer, and cellular senescence (Table 2 and Figure 4).

### ***Survival analysis***

Kaplan-Meier univariate survival analysis was performed using the combined clinical information and gene expression profiles of 205 lncRNAs, 26 miRNAs and 143 mRNAs in the ceRNA network in WT samples. According to the analysis, 14 lncRNAs among 205 DELs were closely related to the overall survival of WT patients (Figure 5). For AC005609.1, AC135178.1, AL391832.1, AL445228.2, DENND5B-AS1, DLEU2, GRM7-AS3, LINC00303 and LINC00473, low expression was related to a high overall survival rate in WT patients. High expression of ADAMTS9-AS1, MEG3, MYB-AS1, NRG1-IT1, and RMST was related to high survival rates in WT patients. In addition, 1 miRNA among 26 DEMs was closely related to the prognosis of WT patients (Figure 6). High expression of hsa-mir-200a was related to high survival rates in WT patients. Eight mRNAs among 143 DEGs were closely related to the overall survival of WT patients (Figure 7). For CDCA4, CEP55, DEPDC1, OSR1, PHF19 and PLEKHA8, low expression was related to a high overall survival rate in WT patients. High expression of KIAA0922 and ZBTB4 was significantly related to high survival rates in WT patients.

## **Discussion**

WT is a type of paediatric renal malignancy. Although overall survival in WT patients is constantly improved, disease recurrence and poor prognosis are still the main causes of cancer-related death in childhood [1]. Dysregulated genes are considered to be the major cause of tumorigenesis in WT. Recently, increasing attention has been paid to the crucial roles of the ceRNA network in gene expression regulation at the transcription, post-transcription and translation levels). A previous study reported the regulatory role of ceRNA networks in the proliferation, metastasis and invasion of cancer [14, 15]. To better understand how the ceRNA regulatory network affects WT, large-scale WT data from the TARGET database were analysed, and a dysregulated ceRNA regulatory network in WT was successfully

constructed. A dysregulated ceRNA network in WT was constructed according to the interactions of 980 DEL–DEM pairs and 235 DEM–DEG pairs between 205 DELs, 26 DEMs, and 143 DEGs. In addition, Kaplan-Meier curves were generated to identify prognostic biomarkers in WT. Fourteen differentially expressed lncRNAs (AC005609.1, AC135178.1, ADAMTS9-AS1, AL391832.1, AL445228.2, DENND5B-AS1, DLEU2, GRM7-AS3, LINC00303, LINC00473, MEG3, MYB-AS1, NRG1-IT1, and RMST), 1 differentially expressed miRNA (hsa-mir-200a) and 8 differentially expressed mRNAs (CDCA4, CEP55, DEPDC1, KIAA0922, OSR1, PHF19, PLEKHA8, and ZBTB4) were shown to be significantly associated with the overall survival rate in WT.

Long noncoding RNAs (lncRNAs) are defined as noncoding RNAs longer than 200 nucleotides [16]. lncRNAs were shown to be involved in a variety of biological regulatory functions, including metastasis and tumorigenesis of cancer [17, 18]. A total of 1,247 upregulated and 790 downregulated DELs were identified in the present study. A total of 205 DELs were included in the construction of the ceRNA network. Additionally, 14 out of the 205 DELs were associated with overall survival in WT patients ( $P < 0.05$ ). Some differentially expressed lncRNAs in our analysis have been investigated in WT: for example, LINC00473 was shown to be capable of decreasing miR-195 expression levels and inhibiting miR-195 function in WT [4]. A dysregulated lncRNA signature including LINC00473/miR-195/IKK $\alpha$  was shown to play a protumorigenic pathogenesis role in WT [4]. The abovementioned molecular experiments partially supported our results in the present study. The identified lncRNAs might serve as prognostic biomarkers and therapeutic targets in WT. In previous studies, RMST was shown to possibly inhibit cell proliferation, invasion, and migration, enhance cell apoptosis, and regulate the cell cycle to act as a tumour suppressor in triple-negative breast cancer [19]. MEG3, a myeloid-related lncRNA, plays a tumour suppressor role in various solid neoplasms [20, 21]. DLEU2 was shown to control miR-16-1 to regulate proliferation, invasion and migration in laryngeal cancer [22]. ADAMTS9-AS1 was related to the overall survival of breast cancer [23], bladder cancer [24] and colon adenocarcinoma [25] patients. Few studies, however, have explored the relationship between the abovementioned DELs and tumorigenesis in WT. Additionally, little is known about the regulatory role of LINC00303, GRM7-AS3, DLEU2, DENND5B-AS1, AL445228.2, AL391832.1, AC135178.1 and AC005609.1 in cancer. Therefore, further studies are needed to illuminate the molecular and biological mechanisms of these DELs in WT.

MicroRNAs are single-stranded and 18-25 nucleotide-long noncoding RNAs that target mRNAs to control gene expression [26]. DEMs in WT, including 105 upregulated and 49 downregulated DEMs, were summarized in the present study. In the present study, the ceRNA network contained 14 differentially expressed miRNAs. However, only one miRNA (miR-200a) was related to overall survival in WT patients. miR-200a is an important member of the miR-200 family. It has been reported that miR-200a participates in several biological processes to control the progression of cancer [27, 28]. miR-200a was shown to target FOXA1 and act as a tumour suppressor in the survival, proliferation and invasion of glioma cells [28]. In addition, miR-200a might inactivate BRD4-mediated AR signalling to inhibit the progression of prostate cancer [27]. Moreover, previous studies have reported that miR-200a participates in the development and occurrence of oesophageal cancer, breast cancer and endometrial cancer by targeting specific genes, such as CRMP-1, EPHA2 and PTEN [29-31]. However, there is no research to clearly

elucidate the role of miR-200a in WT. The understanding of the role of miR-200a in the progression of WT is limited and requires more targeted molecular studies.

To further investigate the related cellular mechanisms in WT, GO and KEGG analyses of 143 DEGs in the ceRNA network were performed. The GO analysis results showed that the DEGs were mainly enriched in terms related to response to mechanical stimuli, transcription factor complexes and transcription factor activity (related to RNA polymerase II proximal promoter sequence-specific DNA binding). The KEGG analysis results indicated that DEGs in the ceRNA network were mainly enriched in pathways related to the cell cycle, small-cell lung cancer, p53 signalling, microRNAs in cancer, and cellular senescence. In recent years, many studies have reported the same findings. The PI3K-AKT-p53 signalling pathway is involved in the tumorigenesis of WT and might represent a potential target in the future [32]. MiRNAs, which are single-stranded and 18-25-nucleotide-long noncoding RNAs [26], were involved in regulating proliferation, the cell cycle and apoptosis in WT [33, 34]. Cellular senescence was reported to be responsible for restricted proliferation in WT, and this result was linked to increased p21 expression and was independent of p53 expression [35]. The abovementioned related studies and experiments partially support our GO and KEGG analysis results in the present study.

The major limitation of the present study is that confirmation of the differentially expressed lncRNAs, miRNAs, mRNA and relative pathways in tumour tissues and blood is lacking. Further targeted studies related to this ceRNA network need to be designed to verify and investigate these valuable ncRNAs in the progression of WT.

## Conclusion

In summary, differentially expressed lncRNAs, mRNAs, and miRNAs were identified, and a functional lncRNA-miRNA-mRNA ceRNA regulatory network for WT tumorigenesis was successfully constructed. Significantly altered lncRNAs, miRNAs and mRNAs might serve as prognostic biomarkers and therapeutic targets for tumorigenesis in WT. The ceRNA regulatory network might illuminate the inner molecular mechanism involved in the progression and tumorigenesis of WT.

## List Of Abbreviations

WT: Wilms tumour

ceRNA: competitive endogenous RNA

TARGET: Therapeutically Applicable Research to Generate Effective Treatment

lncRNA: long non-coding RNA

miRNA: microRNA

DEGs: differentially expressed lncRNAs

DEMs: differentially expressed miRNAs

DEGs: differentially expressed genes

FDR: false discovery rate

GO: Gene Ontology

KEGG: Kyoto Encyclopedia of Genes and Genomes

## Declarations

### *Acknowledgements*

The authors would like to thank Mr. Weipeng Zheng at the Department of Orthopedics, Guangzhou First People's Hospital, Guangzhou Medical University (Guangzhou, China), for his assistance in the use of the R programming language.

### *Authors' contributions*

ZH, FT and ZL conceived the study. ZH, FT, ZL, JW and ZL obtained data and performed statistical analyses. FT, ZL and JW wrote the paper. WW and HD critically read the manuscript. ZH revised the manuscript. All of the authors read and approved the manuscript.

### *Funding*

The present study was supported by a research start-up fee for the Eighth Affiliated Hospital, Sun Yat-sen University (grant no. zdbkyqdf005).

### *Availability of data and materials*

The datasets used and analysed during the current study were downloaded from the Therapeutically Applicable Research to Generate Effective Treatment database (<https://ocg.cancer.gov/programs/target>).

### *Ethics approval and consent to participate*

In the present study, the data were downloaded from the Therapeutically Applicable Research to Generate Effective Treatment database; therefore, this article does not contain any studies with human participants or animals performed by any of the authors. Thus, no ethical approval or patient consent were required.

### *Consent for publication*

Not applicable.

### *Competing interests*

All authors declare that they have no competing interests.

## Authors' information

<sup>1</sup>Department of Urology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518033, China.

<sup>2</sup>First Clinical College of Guangzhou Medical University, Guangzhou 510230, China. <sup>3</sup>Department of Urology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China. <sup>4</sup>Third Clinical College of Guangzhou Medical University, Guangzhou 510230, China.

\*Fucui Tang, Zechao Lu and Jiaming Wang contributed equally to this work.

## References

1. Routh JC, Grundy PE, Anderson JR, Retik AB, Kurek KC. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor. *J Urol*. 2013;189:1487-92.
2. Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms tumor study group. *Pediatr Blood Cancer*. 2008;50:236-41.
3. Cone EB, Dalton SS, Van Noord M, Tracy ET, Rice HE, Routh JC. Biomarkers for Wilms tumor: a systematic review. *J Urol*. 2016;196:1530-5.
4. Zhu S, Fu W, Zhang L, Fu K, Hu J, Jia W, et al. LINC00473 antagonizes the tumour suppressor miR-195 to mediate the pathogenesis of Wilms tumour via IKKalpha. *Cell Prolif*. 2018;51. doi:10.1111/cpr.12416.
5. Liu K, He B, Xu J, Li Y, Guo C, Cai Q, et al. miR-483-5p targets MKNK1 to suppress Wilms' tumor cell proliferation and apoptosis *in vitro* and *in vivo*. *Med Sci Monit*. 2019;25:1459-68.
6. Jia W, Deng Z, Zhu J, Fu W, Zhu S, Zhang LY, et al. Association between HACE1 gene polymorphisms and Wilms' tumor risk in a Chinese population. *Cancer Invest*. 2017;35:633-8.
7. Schwartz MH, Wang H, Pan JN, Clark WC, Cui S, Eckwahl MJ, et al. Microbiome characterization by high-throughput transfer RNA sequencing and modification analysis. *Nat Commun*. 2018;9:5353.
8. Xu Y, Chen J, Yang Z, Xu L. Identification of RNA expression profiles in thyroid cancer to construct a competing endogenous RNA (ceRNA) network of mRNAs, long noncoding RNAs (lncRNAs), and microRNAs (miRNAs). *Med Sci Monit*. 2019;25:1140-54.
9. Liu Q, Deng J, Wei X, Yuan W, Ma J. Integrated analysis of competing endogenous RNA networks revealing five prognostic biomarkers associated with colorectal cancer. *J Cell Biochem*. 2019; doi:10.1002/jcb.28403.
10. Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. *Bioinformatics*. 2012;28:2062-3.

11. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. *Nucleic Acids Res.* 2018;46:D296-302.
12. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. *Nucleic Acids Res.* 2015;43:D146-52.
13. Park K, Kim KB. miRTar hunter: a prediction system for identifying human microRNA target sites. *Mol Cells.* 2013;35:195-201.
14. Zhang S, Ding L, Li X, Fan H. Identification of biomarkers associated with the recurrence of osteosarcoma using ceRNA regulatory network analysis. *Int J Mol Med.* 2019;43:1723-33.
15. Tian W, Jiang C, Huang Z, Xu D, Zheng S. Comprehensive analysis of dysregulated lncRNAs, miRNAs and mRNAs with associated ceRNA network in esophageal squamous cell carcinoma. *Gene.* 2019;696:206-18.
16. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. *Cancer Res.* 2017;77:3965-81.
17. Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. *Biochem J.* 2017;474:4219-51.
18. Sun W, Yang Y, Xu C, Guo J. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. *Cancer Genet.* 2017;216-217:105-10.
19. Wang L, Liu D, Wu X, Zeng Y, Li L, Hou Y, et al. Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): expression analysis and biological roles research. *J Cell Physiol.* 2018;233:6603-12.
20. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. *Endocrinology.* 2010;151:939-47.
21. Lyu Y, Lou J, Yang Y, Feng J, Hao Y, Huang S, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. *Leukemia.* 2017;31:2543-51.
22. Xie ZZ, Xiao ZC, Song YX, Li W, Tan GL. Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. *Eur Rev Med Pharmacol Sci.* 2018;22:1963-70.
23. Fan CN, Ma L, Liu N. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. *J Transl Med.* 2018;16:264.
24. Zhu N, Hou J, Wu Y, Liu J, Li G, Zhao W, et al. Integrated analysis of a competing endogenous RNA network reveals key lncRNAs as potential prognostic biomarkers for human bladder cancer. *Medicine (Baltimore).* 2018;97:e11887.
25. Xing Y, Zhao Z, Zhu Y, Zhao L, Zhu A, Piao D. Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. *Oncol Rep.* 2018;39:2365-75.

26. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. *Nat Rev Drug Discov.* 2017;16:203-22.
27. Guan H, You Z, Wang C, Fang F, Peng R, Mao L, et al. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway. *Cancer Med.* 2019;8:1474-85.
28. Chen X, Liu K, Yang P, Kuang W, Huang H, Tu E, et al. microRNA-200a functions as a tumor suppressor by targeting FOXA1 in glioma. *Exp Ther Med.* 2019;17:221-9.
29. Zang Y, Tai Y, Wan B, Jia X. miR-200a-3p promotes the proliferation of human esophageal cancer cells by post-transcriptionally regulating cytoplasmic collapsin response mediator protein-1. *Int J Mol Med.* 2016;38:1558-64.
30. Wu Q, Lu RL, Li JX, Rong LJ. MiR-200a and miR-200b target PTEN to regulate the endometrial cancer cell growth *in vitro*. *Asian Pac J Trop Med.* 2017;10:498-502.
31. Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. *Carcinogenesis.* 2015;36:1051-60.
32. Zhang M, Xue E, Shao W. Andrographolide promotes vincristine-induced SK-NEP-1 tumor cell death via PI3K-AKT-p53 signaling pathway. *Drug Des Devel Ther.* 2016;10:3143-52.
33. Zhao XS, Han B, Zhao JX, Tao N, Dong CY. MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. *Eur Rev Med Pharmacol Sci.* 2019;23:1030-7.
34. Li H, Huang D, Hang S. Salidroside inhibits the growth, migration and invasion of Wilms' tumor cells through down-regulation of miR-891b. *Life Sci.* 2019;222:60-8.
35. Theerakitthanakul K, Khruethong J, Kruatong J, Graidist P, Raungrut P, Kayasut K, et al. Senescence process in primary Wilms' tumor cell culture induced by p53 independent p21 expression. *J Cancer.* 2016;7:1867-76.

## Tables

**Table 1.** The top 10 upregulated and downregulated differentially expressed genes.

Genesymbol	LogFC	Subtype	FDR	Change
AC093702.1	11.75304022	LncRNA	2.01E-19	Up
LINC01807	10.67432032	LncRNA	1.69E-08	Up
PCDH9-AS1	10.30383735	LncRNA	1.88E-05	Up
AL162413.1	10.26553625	LncRNA	0.000295922	Up
AC006206.2	10.21420894	LncRNA	8.28E-06	Up
AL390115.1	9.729226944	LncRNA	1.19E-08	Up
UG0898H09	9.427695354	LncRNA	9.76E-26	Up
AC247036.1	9.286751894	LncRNA	5.88E-06	Up
DUXAP8	9.25496143	LncRNA	0.000437101	Up
AC022858.1	9.063334433	LncRNA	3.24E-16	Up
AC093583.1	-10.96822749	LncRNA	1.49E-245	Down
LINC01187	-9.174377289	LncRNA	6.88E-68	Down
AC087379.2	-9.017856086	LncRNA	2.11E-53	Down
AC073172.1	-8.966181441	LncRNA	7.03E-78	Down
LINC00284	-8.757230026	LncRNA	2.03E-91	Down
LINC02121	-8.537836046	LncRNA	2.95E-35	Down
AC124017.1	-8.365347845	LncRNA	3.87E-156	Down
UCA1	-7.89490469	LncRNA	2.23E-66	Down
LINC02437	-7.873710855	LncRNA	1.57E-56	Down
LINC00982	-7.628461662	LncRNA	2.29E-34	Down
hsa-mir-383	9.298659023	miRNA	4.06E-06	Up
hsa-mir-1269a	7.525185748	miRNA	0.000415743	Up
hsa-mir-1269b	6.968194063	miRNA	0.046671257	Up
hsa-mir-767	6.775915413	miRNA	0.006257893	Up
hsa-mir-548f-1	6.766938092	miRNA	1.24E-07	Up
hsa-mir-2115	6.512683834	miRNA	4.88E-05	Up
hsa-mir-301b	6.276573984	miRNA	1.89E-10	Up
hsa-mir-105-1	6.260382994	miRNA	0.019280135	Up
hsa-mir-483	6.210785374	miRNA	1.38E-11	Up
hsa-mir-105-2	5.578850103	miRNA	0.025007756	Up
hsa-mir-934	-8.458976144	miRNA	8.18E-109	Down
hsa-mir-203a	-5.559616525	miRNA	2.43E-29	Down
hsa-mir-29c	-4.184218278	miRNA	8.62E-46	Down
hsa-mir-506	-4.068436968	miRNA	7.11E-10	Down
hsa-mir-29a	-4.000404843	miRNA	1.54E-26	Down
hsa-mir-30a	-3.996893892	miRNA	7.42E-27	Down
hsa-mir-514a-1	-3.966692055	miRNA	6.42E-12	Down
hsa-mir-514a-2	-3.896476522	miRNA	2.33E-13	Down
hsa-mir-514a-3	-3.863700282	miRNA	5.84E-12	Down
hsa-mir-203b	-3.503204575	miRNA	1.32E-06	Down
MYL1	13.24180081	mRNA	0.016634278	Up
SIX2	12.51605746	mRNA	7.12E-40	Up
LIN28B	12.3533245	mRNA	1.86E-06	Up
DGKK	12.1463413	mRNA	2.92E-16	Up
SLC32A1	12.07892059	mRNA	6.16E-15	Up
PRAC1	11.60603916	mRNA	0.025719602	Up
VSTM2B	11.49565361	mRNA	2.18E-11	Up
PDYN	11.47837196	mRNA	5.87E-08	Up
DLK1	11.38084591	mRNA	4.70E-07	Up
CHRNA1	11.35683528	mRNA	2.26E-16	Up
UMOD	-18.32990509	mRNA	1.01E-105	Down

AQP2	-13.93867978	mRNA	3.73E-188	<i>Down</i>
KNG1	-12.65984726	mRNA	1.45E-142	<i>Down</i>
FXYD4	-12.05988592	mRNA	4.23E-79	<i>Down</i>
GP2	-10.99884235	mRNA	6.06E-73	<i>Down</i>
SLC9A4	-10.4495998	mRNA	6.00E-124	<i>Down</i>
SLC12A1	-10.42592663	mRNA	4.25E-130	<i>Down</i>
CLCNKA	-10.25241114	mRNA	3.78E-198	<i>Down</i>
BSND	-10.05878694	mRNA	7.49E-148	<i>Down</i>
HRG	-10.05099801	mRNA	1.98E-134	<i>Down</i>


Abbreviations: FC, fold change; FDR, false discovery rate.

**Table 2.** The enriched GO terms (top 5) and KEGG pathways (top 5) of the DEGs

Category	Term	ID	Count	FDR
GO BP	response to mechanical stimulus	GO:0009612	11	0.001184756
GO BP	G1/S transition of mitotic cell cycle	GO:0000082	12	0.001333555
GO BP	cell cycle G1/S phase transition	GO:0044843	12	0.001784413
GO BP	muscle cell proliferation	GO:0033002	10	0.002607351
GO BP	mesenchymal cell differentiation	GO:0048762	9	0.009770918
GO CC	transcription factor complex	GO:0005667	10	0.01896361
GO CC	cyclin-dependent protein kinase holoenzyme complex	GO:0000307	4	0.01896361
GO CC	nuclear chromatin	GO:0000790	10	0.01896361
GO CC	nuclear transcription factor complex	GO:0044798	7	0.024102204
GO CC	Flemming body	GO:0090543	3	0.037639391
GO MF	transcription factor activity, RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000982	15	0.000130468
GO MF	transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding	GO:0001228	15	0.000130468
GO MF	proximal promoter sequence-specific DNA binding	GO:0000987	14	0.000902732
GO MF	transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0001077	11	0.000902732
GO MF	transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding	GO:0001227	10	0.000902732
KEGG	Cell cycle	hsa04110	10	6.52E-06
KEGG	Small cell lung cancer	hsa05222	8	4.96E-05
KEGG	p53 signaling pathway	hsa04115	7	7.55E-05
KEGG	MicroRNAs in cancer	hsa05206	12	0.00013503
KEGG	Cellular senescence	hsa04218	9	0.000137065


Abbreviations: FDR, false discovery rate.

## Figures




**Figure 1**

The flow chart of the analysis procedure. TARGET: Therapeutically Applicable Research to Generate Effective Treatment; DELs: differentially expressed lncRNAs; DEMs: differentially expressed miRNAs; DEGs: differentially expressed genes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis;




**Figure 2**

Heatmap analysis of differentially expressed lncRNAs (a), miRNAs (b), and mRNAs (c) (top 30). Each row represents a sample, and each column represents an lncRNA, miRNA, or mRNA. High or low relative expression is displayed as a red or green strip, respectively.




**Figure 3**

Competitive endogenous RNA (ceRNA) regulation network of 205 lncRNAs, 26 miRNAs and 143 mRNAs in Wilms tumor. The red diamond indicates the upregulated lncRNAs, blue diamond indicates the downregulated lncRNAs; The red triangle indicates the upregulated miRNAs, blue triangle indicates the downregulated miRNAs; The red circle indicates the upregulated mRNAs, blue circle indicates the downregulated mRNAs; Connectivity of two nodes were expressed as edge number. lncRNA, long noncoding RNA; miRNA, microRNA; mRNA, messenger RNA.



**Figure 4**

The top 20 Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of genes involved in the ceRNA regulation network of Wilms tumor. The X-axis represents the GeneRatio for the proportion of genes related GeneRatio, with the top 20 KEGG terms shown on the Y-axis; The graph displays only top 20 KEGG terms. In this graph, the color change between blue and red denote the significance of the correlation between low and high, and the different size of a dot represents related mRNA numbers.



**Figure 5**

Kaplan-Meier curve of the lncRNAs that are significantly associated with OS in Wilms tumour patients. (a) AC005609.1, (b) AC135178.1, (c) RMST, (d) NRG1-IT1, (e) MYB-AS1, (f) MEG3, (g) LINC00473, (h) LINC00303, (i) GRM7-AS3, (j) DLEU2, (k) DENND5B-AS1, (l) AL445228.2, (n) AL391832.1, and (m) ADAMTS9-AS1. The red and blue curves represent samples with higher and lower expression of lncRNAs, respectively.





Figure 6

Kaplan-Meier curve of hsa-mir-200a that are significantly associated with overall survival in Wilms tumor patients. The red and blue curve represents samples with a higher and lower expression of miRNAs, respectively.



**Figure 7**

Kaplan-Meier curve of the mRNAs that are significantly associated with OS in Wilms tumour patients. (a) OSR1, (b) DEPDC1, (c) PLEKHA8, (d) PHF19, (e) CEP55, (f) CDCA4, (g) KIAA0922, and (h) ZBTB4. The red and blue curves represent samples with higher and lower expression of mRNAs, respectively.